Share on LinkedInShare on LinkedIn

ARTICLE · 30 SEPTEMBER 2015

PTAB Refuses To Sanction Kyle Bass

Many pharmaceutical companies have complained about the IPR petitions filed by Kyle Bass and the Coalition for Affordable Drugs against Orange Book-listed patents covering approved pharmaceutical products.

United StatesIntellectual Property

Many pharmaceutical companies have complained about the IPR petitions filed by Kyle Bass and the Coalition for Affordable Drugs against Orange Book-listed patents covering approved pharmaceutical products, but Celgene Corp. took more serious action, and filed motions for sanctions in the IPRs launched against its patents relating to Thalomid® (thalidomide) and Revlamid® (lenalidomide). However, the USPTO Patent Trial Appeal Board (PTAB) refused to sanction Bass on the grounds raised by Celgene. This means patent owners looking for general relief from hedge-fund sponsored patent challenges will have to hope the Federal Circuit sees it differently (assuming Celgene appeals) or that Congress takes action to limit the ability of non-competitors to file IPR petitions.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from